Lunit's AI solutions for cancer screening and treatment are now deployed in over 3,500 global sites, enhancing diagnostic performance for cancer detection.
The deployment of Lunit's AI solutions in over 3,500 sites globally represents a significant market penetration and validation of their technology in real-world clinical settings. This scale of adoption indicates growing trust and integration of AI in medical diagnostics, particularly for cancer screening. It suggests that Lunit's AI is proving effective in enhancing diagnostic performance, potentially leading to earlier and more accurate cancer detection, which can improve patient outcomes and reduce healthcare costs. This widespread use also positions Lunit as a leading player in the medical AI market, attracting further investment and partnerships.
Lunit's AI solutions for cancer screening are now deployed in over 3,500 global sites.
The AI solutions cover chest x-ray and mammography diagnostics.
This deployment signifies strong market adoption and validation of Lunit's technology.
The deployment is global, with specific mention of Lunit CXR Triage being available in the US only for emergency department use. The company headquarters are in Boston, Massachusetts, US, with an additional location in Amsterdam, NL.
This deployment signifies strong market adoption and validation of Lunit's technology.
Lunit INSIGHT CXR Triage is available in the US for emergency departments.
Sign in to save notes on signals.
Sign In